APA (7th ed.) Citation

TT, S., A, K., M, O., M, P., R, O., S, A., . . . HU, A. (2023). Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6): 598-605]. European urology, 83(4), e117. https://doi.org/10.1016/j.eururo.2023.01.004

Chicago Style (17th ed.) Citation

TT, Shah, et al. "Corrigendum to "Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Prior to Salvage Focal Therapy/ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6): 598-605]." European Urology 83, no. 4 (2023): e117. https://doi.org/10.1016/j.eururo.2023.01.004.

MLA (9th ed.) Citation

TT, Shah, et al. "Corrigendum to "Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Prior to Salvage Focal Therapy/ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6): 598-605]." European Urology, vol. 83, no. 4, 2023, p. e117, https://doi.org/10.1016/j.eururo.2023.01.004.